Gillian Atkinson Email

VP Autoimmune Franchise, Product Development . Sangamo Therapeutics

Current Roles

Employees:
436
Revenue:
$108.5M
About
Sangamo BioSciences (Nasdaq: SGMO) develops and markets novel transcription factors capable of regulating genes. The company’s powerful Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression, and consequently, cell function
Sangamo Therapeutics Address
7000 Marina Boulevard
Brisbane, CA
United States
Sangamo Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.